Published in J Biol Chem on March 14, 2005
Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer (2011) 1.12
Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res (2008) 1.02
Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. Nat Commun (2015) 0.92
Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC). Clin Epigenetics (2015) 0.91
Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma. Cell Signal (2011) 0.89
Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer. Transl Oncol (2013) 0.88
Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2). Proc Natl Acad Sci U S A (2008) 0.87
The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer. Mol Cancer Ther (2014) 0.82
Rap1 and its regulatory proteins: the tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer. Small GTPases (2012) 0.81
G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer? Toxins (Basel) (2015) 0.79
Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clin Exp Metastasis (2015) 0.79
Mechanisms of cancer dissemination along nerves. Nat Rev Cancer (2016) 0.78
Galanin plays an important role in cancer invasiveness and is associated with poor prognosis in stage II colorectal cancer. Oncol Rep (2014) 0.77
Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci (2013) 0.77
A Pyrosequencing Assay for the Quantitative Methylation Analysis of GALR1 in Endometrial Samples: Preliminary Results. Biomed Res Int (2015) 0.75
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res (2008) 3.76
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev (2005) 3.33
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature (2007) 2.56
Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett (2008) 2.55
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck (2010) 2.51
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol (2006) 2.47
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
Dental pulp tissue engineering with stem cells from exfoliated deciduous teeth. J Endod (2008) 2.19
Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects. Circ Res (2006) 2.15
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res (2010) 2.11
Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs. Science (2007) 1.89
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther (2007) 1.80
Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay. Mol Pharmacol (2006) 1.78
Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol (2002) 1.75
Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther (2005) 1.70
Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology (2008) 1.68
Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther (2014) 1.61
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev (2013) 1.60
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia (2006) 1.55
Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res (2007) 1.53
Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele. Mol Cell Biol (2006) 1.51
Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss. J Neurosci (2004) 1.48
A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protien-mediated kinetic scaffolding. J Biol Chem (2002) 1.46
UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head Neck (2011) 1.45
Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J Biol Chem (2003) 1.44
Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia (2009) 1.42
Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells. Cancer Chemother Pharmacol (2007) 1.41
P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck (2003) 1.40
AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem (2002) 1.37
N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. Mol Pharmacol (2007) 1.35
Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res (2008) 1.35
International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev (2005) 1.35
Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res (2006) 1.34
Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck (2002) 1.32
Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer (2010) 1.32
Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg (2010) 1.31
Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys (2007) 1.31
Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J Biol Chem (2004) 1.30
Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics (2011) 1.29
Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells. J Biol Chem (2002) 1.28
Regulators of G protein signaling & drugs of abuse. Mol Interv (2005) 1.26
Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol (2006) 1.26
Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res (2004) 1.24
Reversible, allosteric small-molecule inhibitors of regulator of G protein signaling proteins. Mol Pharmacol (2010) 1.23
HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck (2010) 1.23
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther (2008) 1.22
Rap1A and rap1B ras-family proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene (2003) 1.22
Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem (2002) 1.21
Endogenous RGS proteins modulate SA and AV nodal functions in isolated heart: implications for sick sinus syndrome and AV block. Am J Physiol Heart Circ Physiol (2007) 1.21
Regulators of G protein signaling proteins as targets for drug discovery. Prog Mol Biol Transl Sci (2010) 1.20
RGS inhibition at G(alpha)i2 selectively potentiates 5-HT1A-mediated antidepressant effects. Proc Natl Acad Sci U S A (2010) 1.19
Polyplexed flow cytometry protein interaction assay: a novel high-throughput screening paradigm for RGS protein inhibitors. J Biomol Screen (2009) 1.18
RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood (2010) 1.18
Assembly of high order G alpha q-effector complexes with RGS proteins. J Biol Chem (2008) 1.16
Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem (2004) 1.16
Thinking outside of the "RGS box": new approaches to therapeutic targeting of regulators of G protein signaling. Mol Pharmacol (2010) 1.15
Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2003) 1.14
Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett (2009) 1.14
A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol Pharmacol (2008) 1.13
Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues. J Biol Chem (2004) 1.12
Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer (2011) 1.12
Stimulation of cellular signaling and G protein subunit dissociation by G protein betagamma subunit-binding peptides. J Biol Chem (2003) 1.12
Allosteric inhibition of the regulator of G protein signaling-Galpha protein-protein interaction by CCG-4986. Mol Pharmacol (2010) 1.11
RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. Methods Enzymol (2004) 1.10
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Mechanism of action and structural requirements of constrained peptide inhibitors of RGS proteins. Chem Biol Drug Des (2006) 1.08
Ligand-receptor-G-protein molecular assemblies on beads for mechanistic studies and screening by flow cytometry. Mol Pharmacol (2003) 1.07
A nanomolar-potency small molecule inhibitor of regulator of G-protein signaling proteins. Biochemistry (2011) 1.07
Phase-locked signals elucidate circuit architecture of an oscillatory pathway. PLoS Comput Biol (2010) 1.07
Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region. J Interferon Cytokine Res (2011) 1.07
Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res (2009) 1.07
Use of flow cytometric methods to quantify protein-protein interactions. Curr Protoc Cytom (2010) 1.07
Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck (2002) 1.06
The gene ratios c-MYC:cyclin-dependent kinase (CDK)N2A and CCND1:CDKN2A correlate with poor prognosis in squamous cell carcinoma of the head and neck. Clin Cancer Res (2003) 1.06
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response. J Biomol Screen (2011) 1.05
Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses. J Infect Dis (2009) 1.05
Detection of G protein-selective G protein-coupled receptor (GPCR) conformations in live cells. J Biol Chem (2013) 1.05
A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss. J Pharmacol Exp Ther (2006) 1.04
Targeting mRNA stability arrests inflammatory bone loss. Mol Ther (2008) 1.04
Inverse agonist activity of agouti and agouti-related protein. Peptides (2003) 1.03
Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clin Cancer Res (2008) 1.02
Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2010) 1.02